Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

Abstract Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flutter). It is known that patients with cardiovascular disease (CVD) are...

Description complète

Détails bibliographiques

Auteurs principaux:	Juan Carlo Avalon, Jacob Fuqua, Tyler Miller, Seth Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Bianco, Lauren Veltri, Wei Fang, Michael Craig, Abraham Kanate, Kelly Ross, Midhun Malla, Brijesh Patel
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2021-11-01
Collection:	Cardio-Oncology
Sujets:	Ibrutinib Atrial fibrillation Cardio-oncology Cardiovascular disease Arrhythmia Hematologic malignancy
Accès en ligne:	https://doi.org/10.1186/s40959-021-00125-8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!